107 related articles for article (PubMed ID: 8674158)
21. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
[TBL] [Abstract][Full Text] [Related]
22. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
23. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Kreklau EL; Kurpad C; Williams DA; Erickson LC
J Pharmacol Exp Ther; 1999 Dec; 291(3):1269-75. PubMed ID: 10565851
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
25. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
Clutterbuck RD; Millar JL; McElwain TJ
Am J Clin Oncol; 1982 Feb; 5(1):73-8. PubMed ID: 7081141
[TBL] [Abstract][Full Text] [Related]
26. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
27. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
Castellino SM; Friedman HS; Elion GB; Ong ET; Marcelli SL; Page R; Bigner DD; Dewhirst MW
Br J Cancer; 1995 Jun; 71(6):1181-7. PubMed ID: 7779708
[TBL] [Abstract][Full Text] [Related]
28. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
29. Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro.
Chen JM; Zhang YP; Moschel RC; Ikenaga M
Carcinogenesis; 1993 May; 14(5):1057-60. PubMed ID: 8504466
[TBL] [Abstract][Full Text] [Related]
30. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
31. Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.
Thompson MJ; Abdul-Rahman S; Baker TG; Rafferty JA; Margison GP; Bibby MC
J Reprod Fertil; 2000 Jul; 119(2):339-46. PubMed ID: 10864847
[TBL] [Abstract][Full Text] [Related]
32. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593
[TBL] [Abstract][Full Text] [Related]
34. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
35. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
36. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
37. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
38. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
39. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.
Pegg AE; Swenn K; Chae MY; Dolan ME; Moschel RC
Biochem Pharmacol; 1995 Oct; 50(8):1141-8. PubMed ID: 7488227
[TBL] [Abstract][Full Text] [Related]
40. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.
Friedman HS; Colvin OM; Skapek SX; Ludeman SM; Elion GB; Schold SC; Jacobsen PF; Muhlbaier LH; Bigner DD
Cancer Res; 1988 Aug; 48(15):4189-95. PubMed ID: 3390813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]